GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.1 USD | +1.06% |
|
+0.25% | -20.87% |
| 09:57pm | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
| 07:54pm | Sector Update: Health Care Stocks Rise Tuesday Afternoon | MT |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
05/06/2024
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.43
USD
Average target price
82.7
USD
Spread / Average Target
+30.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.87% | 79.02B | |
| +42.83% | 748B | |
| +34.11% | 598B | |
| -5.70% | 356B | |
| +18.06% | 325B | |
| +4.63% | 283B | |
| +17.02% | 245B | |
| +9.26% | 211B | |
| -4.21% | 209B | |
| +2.43% | 166B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Truist Securities Adjusts Gilead Sciences Price Target to $76 From $71, Maintains Hold Rating
